Shandong Xinhua Pharmaceutical Co., Ltd. was established in 1943 in Jiaodong Anti-Japanese Base Area. It is an early chemical synthetic pharmaceutical enterprise in New China. It is an important global production and export base for antipyretic analgesics and painkillers. It is an important domestic cardiovascular and anti-infection. Manufacturers of nervous system, steroid hormone drugs, etc. It has four major business segments: chemical raw materials, pharmaceutical preparations, pharmaceutical intermediates, and e-commerce business, 5 industrial parks and 14 subsidiaries. The annual production capacity of chemical raw materials is 50,000 tons, 500,000 tons of pharmaceutical intermediates, 32 billion solid preparations (particles), and 1.5 billion injections. The annual export volume is nearly US$400 million, and it has established long-term strategic cooperative relations with more than 200 well-known multinational companies including Roche, Bayer, and Bailey. Xinhua Pharmaceutical is a listed company in H-share and A-shares.

Xinhua Pharmaceutical is a national high-tech enterprise, a key high-tech enterprise of the National Torch Plan, and a backbone enterprise of the National Torch Plan biopharmaceutical industry base. It has a national enterprise technology center, and has academician workstations, postdoctoral workstations, Taishan industrial talent positions, Taishan scholar positions, There are six major talent platforms including the Master's Joint Training Point and Shandong Technician Workstation. In recent years, Xinhua Pharmaceutical has increased its school-enterprise cooperation efforts and established comprehensive strategic cooperative relations with the Chinese Academy of Medical Sciences, Tsinghua University, Shandong University, Shenyang Pharmaceutical University, Qingdao University of Science and Technology, etc. Six centers including the Medicinal Chemistry Research Center and the Drug Preparation Research Center have been built, covering 12 directions including digestive system, pain control, cardiovascular and cerebrovascular system, anti-metabolic system, nervous system, nutritional health, hormones, etc. , increase R&D investment and lay out more than 100 new products. A total of 21 products and 27 specifications have passed consistency evaluation, and have 8 national first-class new drug documents and 21 second-class new drug documents and obtained 266 authorized patents. It is a three-star "Chinese Patent Shandong Star Enterprise".

Xinhua Pharmaceutical's quality value of "product quality is related to the life of the enterprise, and drug quality is related to the life of the person" has been thoroughly implemented by all employees and throughout the process. The company focuses on quality investment and has established a quality control system for the entire process from the entry of raw materials into the factory and the production link to the exit of the product. In the 1990s, Xinhua Pharmaceutical won the domestic "Excellent Quality Management Award". 23 products have won high-quality product awards at the provincial and ministerial levels and above, of which 3 products have won the national gold award and 3 products have won the national silver award. At present, all drugs in production in Xinhua Pharmaceutical have passed the national new version of GMP certification, and have obtained 22 US FDA registration documents, 12 EU EDQM documents, and 3 ANDA documents. Xinhua Pharmaceutical Modern Pharmaceutical International Cooperation Center has passed the China NMPA, GMP certifications such as the UK MHRA, the US FDA and the EU, the preparation products produced by the center are qualified to be sold to international markets such as Europe, the US and the UK, and have exported more than 5 billion tablets in total.

In recent years, Xinhua Pharmaceutical has launched a batch of new drugs such as: National Class I innovative drugs, new non-hormonal anti-inflammatory and anti-allergic drugs----------------------------------------------------------------------------------- Shutaide (rabeprazole sodium enteric-coated tablets), Jiaheluo (glimediide tablets), the drug for treating cardiovascular and cerebrovascular treatment (aspirin enteric-coated sustained-release tablets), the National Class 3.1 new drug insurance Chang (Jocal calcium tablets), Fuya'an series three high-purity fish oil health products, and unique dosage form nimodipine sustained-release capsules, the main products are included in the national medical insurance catalog.

As a state-owned holding enterprise with red gene, Xinhua Pharmaceutical has always adhered to the corporate mission of "protecting health and benefiting society" and actively fulfilled its social responsibilities. Especially in the three years of fighting the epidemic, Xinhua People do not uphold conditions, live up to their mission, and do their best to do their best. Production and supply of drugs. Especially since the adjustment of the epidemic prevention and control policy in December 2022, the national allocation task was successfully completed in just over 20 days, and a total of 800 million pieces of ibuprofen and other heat-relieving towns were supplied to 31 provinces (municipalities directly under the central government, autonomous regions) across the country. Pain drugs (most of the ibuprofen tablets in the Beijing market are supplied by Xinhua Pharmaceuticals) have effectively guaranteed the people's drug needs and truly reflected the responsibility of state-owned enterprises. The Ministry of Industry and Information Technology, Beijing, Tsinghua University, Fujian Province, Nanjing, Dalian, Yangzhou City and other cities have successively sent letters of condolences and thanks to Xinhua Pharmaceutical, giving high recognition and praise for Xinhua Pharmaceutical's full efforts to ensure the supply of key drugs for the epidemic.

Over the years, the company has highlighted the connotation of quality, internationalization, science and technology and responsibility, and has created professional characteristics through all-round means, establishing a good image of quality Xinhua, international Xinhua, science and technology Xinhua and responsibility Xinhua. Xinhua Pharmaceuticals was listed in Shandong Province's first batch of "Honorable Shandong Business" five-star brand image list, and won the National Model Labor Relations Harmonious Enterprise, National Green Factory and Green Supply Chain Enterprise, China Quality Integrity Enterprise, Shandong Province All Staff Innovation Enterprise, Shandong The provincial talent work unit, the leading science and technology enterprise in Shandong Province, and the Shandong Province's advanced collective in fighting the new crown pneumonia epidemic are honored.